RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000075.xml
PDF herunterladen
Semin Respir Crit Care Med 2002; 23(3): 261-266
DOI: 10.1055/s-2002-33034
DOI: 10.1055/s-2002-33034
Respiratory Complications of Parkinson's Disease
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
02. August 2002 (online)
ABSTRACT
Patients with Parkinson's disease are at risk for pulmonary complications as a consequence of both the underlying disease pathology and the side effects of medication. Degeneration of the substantia nigra and subsequent loss of dopaminergic neurons may produce changes in ventilatory parameters. Upper airway obstruction and chest wall restriction are both common, and both may respond to levodopa. However, therapy for Parkinson's may also contribute to pulmonary morbidity. Overtreatment with levodopa causes respiratory dyskinesia that may be difficult to differentiate from complications of the disease itself. Therapy with ergot derivatives may cause pleuropulmonary fibrosis. Pneumonia resulting from the respiratory complications remains a significant cause of morbidity and mortality in Parkinson's disease.
KEYWORDS
Parkinson's disease - dopaminergic - levodopa - chest wall rigidity - pulmonary complications
REFERENCES
- 1 Parkinson J. An essay on the shaking palsy.
London: Sherwood, Nealy and Jones; 1817
MissingFormLabel
- 2 Hoehn M M, Yahr M D. Parkinsonism: onset, progression and mortality. Neurology . 1967; 17 427-442
- 3 Schwab R D, England A C, Peterson E. Akinesia in Parkinson's disease. Neurology . 1959; 9 65-72
- 4 Baker K K, Ramig L O, Luschei E S, Smith M E. Thyroarytenoid muscle activity associated with hypophonia in Parkinson disease and aging. Neurology . 1998; 51 1592-1598
- 5 Jankovic J, Cardoso F, Grossman R G, Hamilton W J. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery . 1995; 37 680-687
- 6 Lang A E, Duff J, Saint-Cyr J A. Posteroventral medial pallidotomy in Parkinson's disease. J Neurol . 1999; S28-S41
- 7 Berke G S, Gerratt B, Kreiman J, Jackson K. Treatment of Parkinson hypophonia with percutaneous collagen augmentation. Laryngoscope . 1999; 109 1295-1299
- 8 Hovestadt A, Bogaard J M, Meerwaldt J D. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatry . 1989; 52 329-333
- 9 Fontana G A, Pantaleo T, Lavorini F. Defective motor control of coughing in Parkinson's disease. Am J Respir Crit Care Med . 1998; 158 458-464
- 10 Vincken W G, Gauthier S G, Dollfuss R E. Involvement of upper-airway muscles in extrapyramidal disorders: a cause of airflow limitation. N Engl J Med . 1984; 311 438-442
- 11 Neu H C, Connolly Jr J J, Schwertley F W. Obstructive respiratory dysfunction in parkinsonian patients. Am Rev Respir Dis . 1967; 95 33-47
- 12 Izquierdo-Alonso J L, Jimenez-Jimenez F J, Cabrera-Valdivia F, Mansilla-Lesmes M. Airway dysfunction in patients with Parkinson's disease. Lung . 1994; 172 47-55
- 13 Kinnier-Wilson S A. Neurology.
Baltimore, Md: Willams & Wilkins; 1940
MissingFormLabel
- 14 Sabate M, Gonzalez I, Ruperez F, Rodriguez M. Obstructive and restrictive pulmonary dysfunctions in Parkinson's disease. J Neurol Sci . 1996; 138 114-119
- 15 de Bruin F P, de Bruin M V, Lees A J, Pride N B. Effects of treatment on airway dynamics and respiratory muscle strength in Parkinson's disease. Am Rev Respir Dis . 1993; 148 1576-1580
- 16 Herer B, Arnulf I, Housset B. Effects of levodopa on pulmonary function in Parkinson's disease. Chest . 2001; 119(2) 387-393
- 17 Read D, Young A. Stridor and parkinsonism. Postgrad Med J . 1983; 59 520-521
- 18 Fink M E, Klebanoff L M, Lennihan L, Fahn S. Acute respiratory failure during drug manipulation in patients with Parkinson's disease. Neurology . 1989; 39 348
- 19 Riley D E, Grossman G, Martin L. Acute respiratory failure from dopamine agonist withdrawal. Neurology . 1992; 42 1843-1844
- 20 Easdown L J, Tessler M J, Minuk J. Upper airway involvement in Parkinson's disease resulting in postoperative respiratory failure. Can J Anaesth . 1995; 42 344-347
- 21 Galvez-Jimenez N, Lang A E. Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. Can J Neurol Sci . 1996; 23 198-203
- 22 Nugent C A, Harris H W, Cohn J. Dyspnea as a symptom in Parkinson's syndrome. Am Rev Tuberc . 1958; 78 682-691
- 23 Paulson G D, Tafrate R H. Some ``minor'' aspects of parkinsonism, especially pulmonary function. Neurology . 1970; 20 14-17
- 24 Bateman D N, Cooper R G, Gibson G J. Levodopa dosage and ventilatory function in Parkinson's disease. Br Med J (Clin Res Ed) . 1981; 283 190-191
- 25 Estenne M, Hubert M, De Troyer A. Respiratory-muscle involvement in Parkinson's disease. N Engl J Med . 1984; 311 1516-1517
- 26 Sabate M, Rodriguez M, Mendez E. Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson's disease. Arch Phys Med Rehabil . 1996; 77 29-34
- 27 Apps M C, Sheaff P C, Ingram D A. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry . 1985; 48 1240-1245
- 28 Silber M H, Levine S. Stridor and death in multiple system atrophy. Mov Disord . 2000; 15 699-704
- 29 Chester C S, Gottfried S B, Cameron D I, Strohl K P. Pathophysiological findings in a patient with Shy-Drager and alveolar hypoventilation syndromes. Chest . 1988; 94 212-214
- 30 Weiner W J, Goetz C G, Nausieda P A, Klawans H L. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med . 1978; 88 327-331
- 31 Zupnick H M, Brown L K, Miller A, Moros D A. Respiratory dysfunction due to L-dopa therapy for parkinsonism: diagnosis using serial pulmonary function tests and respiratory inductive plethysmography. Am J Med . 1990; 89 109-114
- 32 Hartman D E. Stridor during dystonia phases of Parkinson's disease. J Neurol Neurosurg Psychiatry . 1988; 51 161
- 33 Vazquez A, Jimenez-Jimenez F J, Garcia-Ruiz P, Garcia-Urra D. ``Panic attacks'' in Parkinson's disease: a long-term complication of levodopa therapy. Acta Neurol Scand . 1993; 87 14-18
- 34 Stacy M. Pharmacotherapy for advanced Parkinson's disease. Pharmacotherapy . 2000; 20(suppl 1, pt 2) S8-S16
- 35 Bhatt M H, Keenan S P, Fleetham J A, Calne D B. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol . 1991; 30 613-616
- 36 Geminiani G, Fetoni V, Genitrini S. Cabergoline in Parkinson's disease complicated by motor fluctuations. Mov Disord . 1996; 11 495-500
- 37 McElvaney N G, Wilcox P G, Churg A, Fleetham J A. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med . 1988; 148 2231-2236
- 38 Todman D H, Oliver W A, Edwards R L. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Clin Exp Neurol . 1990; 27 79-82
- 39 LeWitt P A, Calne D B. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet . 1981; 1 44-45
- 40 Hillerdal G, Lee J, Blomkvist A. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos. Eur Respir J . 1997; 10 2711-2715
- 41 Canning C G, Alison J A, Allen N E, Groeller H. Parkinson's disease: an investigation of exercise capacity, respiratory function, and gait. Arch Phys Med Rehabil . 1997; 78 199-207
- 42 Koseoglu F, Inan L, Ozel S. The effects of a pulmonary rehabilitation program on pulmonary function tests and exercise tolerance in patients with Parkinson's disease. Funct Neurol . 1997; 12 319-325
- 43 Tzelepis G E, McCool F D, Friedman J H, Hoppin Jr G F. Respiratory muscle dysfunction in Parkinson's disease. Am Rev Respir Dis . 1988; 138 266-271